{"id":"f7eacf68-be3e-5ecb-a638-f9c59a2114e7","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-glucuronide-activity","predicate":"decreases_in_recorded_comparison","statement":"Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"9dbe926e-3936-512d-8532-55540d310973","mechanism_event_label":"Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.","subject":{"id":"353de06b-4efb-5810-a466-8f1056a30ecb","slug":"apigenin-7-glucuronide","display_name":"Apigenin 7-O-glucuronide","entity_type_key":"small_molecule"},"object":{"id":"795b855e-070e-50c5-a180-95a04137cb48","slug":"mouse-apigluc-inflammatory-products","display_name":"Inflammatory products in apigenin-glucuronide-treated RAW264.7 cells","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"9dbe926e-3936-512d-8532-55540d310973","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-glucuronide-activity-event","event_type":"experimental_observation","label":"Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.","description":"### api-glucuronide-activity\n\nApigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.\nDo not assume conjugates are inert or assume intracellular parent regeneration; intracellular speciation was not established by this abstract.\nModel and exposure: Mouse macrophage cell line; exposure details unavailable in the accessed abstract.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | 2016 | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"353de06b-4efb-5810-a466-8f1056a30ecb","slug":"apigenin-7-glucuronide","display_name":"Apigenin 7-O-glucuronide","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin 7-O-glucuronide plus LPS","sequence_order":0,"notes":""},{"entity":{"id":"795b855e-070e-50c5-a180-95a04137cb48","slug":"mouse-apigluc-inflammatory-products","display_name":"Inflammatory products in apigenin-glucuronide-treated RAW264.7 cells","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"f2a6b7ab-ad41-5ada-8895-41d6ce42f4e4","slug":"nitric-oxide","display_name":"NO","entity_type_key":"small_molecule"},"role":"measured product","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"Apigenin 7-O-glucuronide plus LPS","comparator":"LPS alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"apigenin-7-glucuronide","display_name":"Apigenin 7-O-glucuronide","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"LPS challenge","comparator":"LPS alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"lipopolysaccharide","display_name":"Lipopolysaccharide","entity_type_key":"chemical_species"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin 7-O-glucuronide plus LPS\", \"comparator\": \"LPS alone\", \"endpoint\": \"Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.\", \"effect_direction\": \"decrease\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"apigenin-7-glucuronide\", \"state\": \"Apigenin 7-O-glucuronide plus LPS\"}, {\"entity_slug\": \"lipopolysaccharide\", \"state\": \"LPS challenge\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Mouse macrophage cell line; exposure details unavailable in the accessed abstract.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-glucuronide-activity; Do not assume conjugates are inert or assume intracellular parent regeneration; intracellular speciation was not established by this abstract.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"d18e7726-1cad-5804-9b1b-9d9b5d40a7d8","evidence_kind":"source_excerpt","locator":"Lines 130-136","start_line":130,"end_line":136,"excerpt":"### api-glucuronide-activity\n\nApigenin 7-O-glucuronide reduced LPS-induced NO, PGE2 and TNF production in RAW264.7 cells.\nDo not assume conjugates are inert or assume intracellular parent regeneration; intracellular speciation was not established by this abstract.\nModel and exposure: Mouse macrophage cell line; exposure details unavailable in the accessed abstract.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | 2016 | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Mouse macrophage cell line; exposure details unavailable in the accessed abstract.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}